Ledipasvir Chiral Impurity 5

Ledipasvir Chiral Impurity 5 is a stereoisomeric byproduct arising from the enantioselective synthesis of the antiviral agent Ledipasvir. It retains the pyrazine-thiophene-sulfonamide core but features an inverted configuration at the chiral α-carbon of the proline-derived side chain, resulting in a non-pharmaceutically active enantiomer. This impurity exhibits distinct diastereomeric interactions during chromatographic resolution, necessitating enantioselective HPLC conditions for quantification. Its structural similarity to the parent drug enables its use as a reference standard for validating chiral separation protocols in quality control.